EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische Studie

EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer

Izuma Nakayama iD, Min-Hee Ryu iD, Sung Hee Lim iD, Jong Gwang Kim, Takeshi Omori, Sang Cheul Oh, Jin Young Kim iD, Sun Young Rha iD, Keun-Wook Lee iD, Nozomu Machida iD, Sun Jin Sym iD, Yukiya Narita iD und 10 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-26-01072 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Izuma Nakayama und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Esophagogastric Junction, Stomach Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

EP4, a key receptor in the PGE 2 axis, mediates tumor immunosuppression; the EP4 antagonist ONO-4578 plus nivolumab showed manageable safety, immune activation, and preliminary antitumor activity in previously treated gastric/gastroesophageal junction cancer (G/GEJC). This study explored whether ONO-4578 enhances the efficacy of nivolumab plus chemotherapy in unresectable advanced or recurrent G/GEJC. Patients and Methods This multicenter, double-blind, randomized phase 2 study enrolled chemotherapy-naïve patients with HER2-negative unresectable advanced or recurrent G/GEJC. Patients were randomized (2:1) to receive oral ONO-4578 or matching placebo, each in combination with nivolumab and oxaliplatin-based chemotherapy. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.

Results

At the data cutoff, 226 patients were randomized to the ONO-4578 group (n = 150) and the placebo group (n = 76). Adding ONO-4578 significantly improved PFS (hazard ratio of 0.67; 90% confidence interval, 0.48–0.92; p-value, 0.040 [prespecified two-sided α = 0.10]), with favorable OS at a prespecified analysis with limited follow-up (hazard ratio of 0.60; 95% confidence interval, 0.37–0.96) and ORR (62.0% vs 48.7%). Exploratory subgroup analyses suggested that ONO-4578 regimen provided greater benefit in PD-L1 CPS ≥1, whereas no clear benefit in CPS

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsEsophagogastric JunctionStomach NeoplasmsNeoplasm Recurrence, LocalNivolumabEsophageal NeoplasmsReceptors, Prostaglandin E, EP4 SubtypeHumansFemaleMaleDouble-Blind MethodAgedMiddle AgedErb-b2 Receptor Tyrosine KinasesAdultProgression-Free SurvivalAntibodies, Monoclonal, HumanizedAged, 80 and overOxaliplatin

Substanzen

Erb-b2 Receptor Tyrosine KinasesNivolumabReceptors, Prostaglandin E, EP4 SubtypeandecaliximabERBB2 protein, humanAntibodies, Monoclonal, HumanizedOxaliplatin

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Oncology/Hematology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Izuma Nakayama, Min-Hee Ryu, Sung Hee Lim, Jin Young Kim, Sun Young Rha, Keun-Wook Lee, Nozomu Machida, Sun Jin Sym, Yukiya Narita, Hiroki Hara, In-Ho Kim, Li-Yuan Bai, Kohei Shitara

Zitieren

APA

Nakayama, I., Ryu, M. H., Lim, S. H., Kim, J. G., Omori, T., Oh, S. C., Kim, J. Y., Rha, S. Y., Lee, K. W., Machida, N., Sym, S. J., Narita, Y., Park, Y. I., Hara, H., Hosaka, H., Kang, B., Kim, I. H., Bai, L. Y., Hirashima, Y., …, & Shitara, K. (2026). EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01072

Vancouver

Nakayama I, Ryu MH, Lim SH, Kim JG, Omori T, Oh SC, et al. EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-01072

BibTeX
@article{Nakayama2026,
  author = {Nakayama, Izuma and Ryu, Min-Hee and Lim, Sung Hee and Kim, Jong Gwang and Omori, Takeshi and Oh, Sang Cheul and Kim, Jin Young and Rha, Sun Young and Lee, Keun-Wook and Machida, Nozomu and Sym, Sun Jin and Narita, Yukiya and Park, Young-Iee and Hara, Hiroki and Hosaka, Hisashi and Kang, Beodeul and Kim, In-Ho and Bai, Li-Yuan and Hirashima, Yoshinori and Hagihara, Shunsuke and Yamamoto, Takanori and Shitara, Kohei},
  title = {EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-01072}
}
Kostenlos starten →